Synergene Therapeutics, Inc.
Clinical trials sponsored by Synergene Therapeutics, Inc., explained in plain language.
-
New hope for kids with tough cancers: experimental drug SGT-53 under study
Disease control TerminatedThis study tests an experimental drug called SGT-53 in children and young adults (ages 1 to 21) with solid tumors that have returned or not responded to standard treatments. The goal is to find the safest dose of SGT-53 when given alone and with chemotherapy drugs topotecan and c…
Phase: PHASE1 • Sponsor: SynerGene Therapeutics, Inc. • Aim: Disease control
Last updated May 26, 2026 12:05 UTC
-
Child brain tumor drug trial pulled before it started
Disease control TerminatedThis study was designed for children with brain or spinal cord tumors that came back or did not respond to treatment. It planned to test an experimental drug called SGT-53 alongside radiation and chemotherapy to see if it was safe. However, the study was withdrawn before any pati…
Phase: EARLY_PHASE1 • Sponsor: SynerGene Therapeutics, Inc. • Aim: Disease control
Last updated May 26, 2026 12:04 UTC